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Summary
Objective: We conducted a study to evaluate the sensitivity and specificity of using CD4+
measurement and clinical evaluation to detect antiretroviral treatment failure in HIV-infected
patients who had received their first regimen of highly active antiretroviral therapy (HAART). The
secondary objective was to determine the prevalence and risk factors of virological failure.
Methods: A retrospective cohort study was conducted at Chiang Mai University Hospital, Thai-
land. Univariate analysis was performed to compare risk ratios between patients with andwithout
virological failure. Sensitivity and specificity of the immunological and/or clinical criteria in
comparison with virological criteria were calculated using 2 by 2 tables.
Results: From January 2003 to December 2005, 327 HIV-infected patients were enrolled. The
median follow-up period was 19 months (range 6—42 months). Virological failure was detected in
9.2% of patients. Patients with a previous history of opportunistic infection had a greater risk for
developing virological failure (OR = 2.66, 95% CI = 1.1—6.4). Using the combined immunological
and clinical criteria to detect antiretroviral treatment failure, the sensitivity was 20.0% and the
specificity was 85.9%.
Conclusions: Our study, which was limited by small numbers, was not able to demonstrate that
immunological or clinical criteria can adequately replace virological criteria for the determination
of treatment failure.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The use of highly active antiretroviral therapy (HAART) is
associated with a significant survival benefit and a dramatic* Corresponding author. Tel.: +66 53 946457; fax: +66 53 894231.
E-mail address: khuanchai@idthai.org (K. Supparatpinyo).
1201-9712/$32.00 # 2006 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2006.11.003reduction in the incidence of opportunistic infections in HIV-
infected patients.1—3 Currently, HAART has become a stan-
dard of care in the treatment of HIV infection inmany parts of
the world.
The outcome of antiretroviral therapy can be monitored
using different methods including virological, immunologi-
cal, and clinical evaluations.4—7 Virological evaluation, i.e.,Published by Elsevier Ltd. All rights reserved.
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standard for monitoring of treatment outcome.8—10 Using this
method, early treatment failure can be detected and a
change to other more effective antiretroviral regimens is
then possible. However, in resource-limited settings, i.e., in
most developing countries including Thailand, the cost of
HAART is high and access to treatment may be relatively
limited.11,12 Adding to this the high cost of periodic viral
measurements makes it almost impossible for all people in
these developing countries to access antiretroviral therapy
with effective monitoring. Therefore, two cheaper surrogate
markers are routinely used to monitor the efficacy of therapy
in the developing world, i.e., clinical assessment and CD4+
cell count. HIV RNA measurement is generally reserved for
use in patients with immunological and/or clinical fail-
ure.11,13
In Thailand, the government provides free access to
HAART for all HIV-infected patients who have indication(s)
for use, following the national guidelines for HIV/AIDS man-
agement developed by the Ministry of Public Health.13 These
treatment guidelines are reviewed annually by panels of
infectious disease and HIV/AIDS experts from throughout
the country. Due to budget limitations, the national guide-
lines recommend performing CD4+ cell counts every 6
months, in addition to routine clinical evaluation, in all
patients who receive HAART.13 It also provides definitions
of antiretroviral treatment failure using immunological and
clinical criteria. HIV RNA measurement is recommended only
in those patients who fulfill the immunological and/or clinical
criteria for treatment failure.
This study was aimed at evaluating the sensitivity and
specificity of using CD4+ measurement and clinical evalua-
tion to detect antiretroviral treatment failure in the
resource-limited setting. The secondary objective was to
determine the prevalence and risk factors of virological
failure in HIV-infected patients who had received their first
regimen of HAART.
Methods
We conducted a retrospective cohort study in HIV-infected
patients who were treated and followed up at the infectious
disease outpatient clinic, Chiang Mai University Hospital from
January 2003 to December 2005. All the subjects had docu-
mented HIV infection and met the following criteria: (1) 15
years of age; (2) had received their first regimen of HAART
following the national guidelines for HIV/AIDS management;
(3) CD4+ cell count had been carried out every 6 months after
initiation of HAART; and (4) HIV RNA measurement had been
carried out at 6 months or later after initiation of HAART.
Definitions of terms
We used the definitions of antiretroviral treatment failure
following the national guidelines for HIV/AIDS management
developed by the Thai Ministry of Public Health.13
Immunological failure: the absence of increase or a
decrease in the CD4+ cell count of more than 30% from
the highest value after at least 6 months of HAART.
Clinical failure: the development of an AIDS-associated
condition or death after at least 6 months of HAART.Virological failure: an HIV RNA measurement of more than
50 copies/ml after at least 6 months of HAART.Data collection
We recorded the following data: (1) demographic character-
istics at the initiation of HAART; (2) CD4+ cell counts at
months 0, 6, 12, and 18 of HAART; and (3) HIV RNA measure-
ments after initiation of HAART.
Statistical analysis
The virological, immunological, and clinical failure preva-
lences are expressed in percentage terms. Demographic
data, medical history, laboratory data, and therapeutic out-
come are expressed in terms of percentage, mean  stan-
standard deviation (SD), and range.
Univariate analysis of demographic and laboratory data of
patients with and without virological failure was performed
to compare risk ratios between groups. Categorical data
were assessed by the Chi-square test or Fisher’s exact test
as appropriate. Continuous data were assessed by the Stu-
dent’s t-test or Mann—Whitney U-test as appropriate. A two-
sided test was used to indicate statistical significance at a p
value of <0.05.
Sensitivity, specificity, positive predictive value, and
negative predictive value of the immunological and/or clin-
ical criteria in comparison with virological criteria were
calculated using 2 by 2 tables.
SPSS software version 13.0 (SPSS for windows, Rel.
13.0.1997; Chicago, USA, SPSS Inc.) was used for all statis-
tical analyses.
Results
Demographic data
During the three-year period from January 2003 to December
2005, 327HIV-infected patientswere enrolled in the study. For
the regimen of HAART, 279 patients (85.3%) received a fixed-
dose combination of stavudine, lamivudine, and nevirapine
(GPO-VIR1, manufactured by the Thai Government Pharma-
ceutical Organization), 16 (4.9%) received a regimen contain-
ing efavirenz plus two nucleoside reverse transcriptase
inhibitors (NRTI), and 32 (9.8%) received a regimen containing
nevirapine plus two NRTIs. There were 140 men (42.8%) and
187women (57.2%) with amean age of 37.8  7.8 years (range
21—65 years). One hundred and eighty-seven patients (57.2%)
had had previous opportunistic infections before initiation of
HAART; these included pneumocystis pneumonia (43 patients,
13.1%), penicilliosis marneffei (32 patients, 9.8%), pulmonary
tuberculosis (26 patients, 8.0%), cryptococcosis (18 patients,
5.5%), and cytomegalovirus retinitis (12 patients, 3.7%).
The mean CD4+ Tcell counts at baseline, 6 months, and 12
months after initiation of HAART were 108.0  117.4,
219.0  146.3, and 273.5  160.0 cells/mm3, respectively.
Prevalence and risk factors of antiretroviral
treatment failure
Among 327 eligible patients, 14 (4.3%), 35 (10.7%), and 16
(4.9%) met the criteria of virological failure, immunological
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Table 1 Demographic characteristics, medical history, and laboratory data of patients with and without virological failure
Characteristics Patients with virological
failure (N = 30)
Patients without virological
failure (N = 297)
p Value
Age, years (mean  SD) 36.7  7.5 38.0  7.8 0.38
Sex male (%) 17 (56.7) 123 (41.41) 0.12
Previous history of opportunistic
infection (%)
23 (76.7) 164 (55.2) 0.03
Baseline CD4+ cell count before
initiation of HAART (mean  SD)
93.3  125.11 109.5  116.7 0.50
HAART, highly active antiretroviral therapy.failure, and clinical failure, respectively. The median follow-
up period was 19 months (range 6—42 months). The compar-
ison of demographic characteristics, medical history, and
laboratory data between the groups of patients with and
without virological failure are shown in Table 1. The uni-
variate analysis revealed only one risk factor for developing
virological failure, i.e., previous history of opportunistic
infection (OR = 2.66, 95% CI = 1.1—6.4).
Sensitivity and specificity of immunological and
clinical criteria
In this study, virological measurement ofmore than 50 copies/
ml was used as the gold standard to evaluate antiretroviral
treatment failure. The correlations between number of
patients with and without virological failure versus immuno-
logical failure, virological failure versus clinical failure, and
virological failure versus immunological and/or clinical failure
were performed using 2 by 2 tables (data not shown here).
Sensitivity, specificity, positive predictive value, and positive
predictive value of using immunological and clinical criteria to
determine antiretroviral treatment failure were calculated
and are shown in Table 2. Sensitivity, specificity, positive
predictive value, and positive predictive value of using com-
bined immunological and clinical criteria to determine viro-
logical failure at different cut-offs are shown in Table 3.Table 2 Sensitivity, specificity, positive predictive value, and posit
to determine antiretroviral treatment failure
Immunological
criteria
Sensitivity (%) 13.3
Specificity (%) 89.6
Positive predictive value (%) 8.6
Negative predictive value (%) 90.8
Table 3 Sensitivity, specificity, positive predictive value, and po
clinical criteria to determine virological failure at different cut-o
Viral load >50
copies/ml
Viral
copie
Sensitivity (%) 20.0 13.3
Specificity (%) 85.9 85.3
Positive predictive value (%) 12.5 4.2
Negative predictive value (%) 91.4 95.3Discussion
Due to significant reductions in cost and thewideavailability of
generic antiretroviral drugs, antiretroviral therapy is currently
affordable even in somedeveloping countries. In Thailand, the
national policy is that all HIV-infected patients in the country
can have access to antiretroviral treatment.14 In this study,
we have shown the efficacy of three antiretroviral treatment
regimens commonly used in Thailand; the fixed-dose combina-
tion of generic antiretroviral drugs (GPO-VIR1) manufactured
by the Thai Government Pharmaceutical Organization is the
most common regimen, being used in 85% of patients.
Virological failure in our study was 9.2% after a median
follow-up duration of 19 months. This result is in the range of
failure rates found in a previous study by Anekthananon et al.
from Bangkok, Thailand (2.4% by on-treatment and 19.8% by
intention-to-treat analysis).15 In addition, our study showed
that a previous history of opportunistic infection was the only
risk factor for virological failure. However, this was a retro-
spective study that was not designed to adequately collect
the data on adherence to antiretroviral therapy. A prospec-
tive studymay bemore appropriate to determine the relative
risk of developing treatment failure in these patients.
In Thailand, the national guidelines for HIV/AIDS man-
agement recommend using clinical and immunological cri-
teria to monitor the outcome of antiretroviral treatment.13ive predictive value of using immunological and clinical criteria
Clinical
criteria
Combined immunological
and clinical criteria
10.0 20.0
95.6 85.9
25.0 12.5
91.6 91.4
sitive predictive value of using combined immunological and
ffs
load >500
s/ml
Viral load >1000
copies/ml
Viral load >5000
copies/ml
14.3 18.2
85.3 85.4
4.2 4.2
95.7 96.6
416 R. Chaiwarith et al.This strategy is generally used in the many countries where
healthcare resources are limited.11 Our study showed that
antiretroviral treatment failure was suspected in 10.7% and
4.9% of patients using immunological criteria and clinical
criteria, respectively. With the use of HIV RNA measurement
as the gold standard, the sensitivities of using either immu-
nological or clinical criteria to determine antiretroviral
treatment failure were found to be extremely low (13.3%
and 10.0%, respectively). However, the specificities of using
these two markers were found to be acceptably high (89.6%
and 95.6%, respectively). Although the 20.0% sensitivity
using the combined clinical and immunological criteria to
detect antiretroviral treatment failure is slightly higher
than the sensitivity using one marker alone, we would
miss 80% of patients who have treatment failure using
virological criteria. Using various virological cut-offs does
not improve the sensitivity and predictive values (Table 3).
These patients, in particular those with a viral load
>1000 copies/ml, need genotypic resistance testing and
proper antiretroviral substitution, but treatment would
be left unchanged. If they continued on a failing antiretro-
viral regimen, it is possible that the resistance mutation
genes would accumulate and cross resistance to all antire-
troviral drugs in the same classes would ultimately
develop.16 In the presence of extensive resistance muta-
tions, change to other effective antiretroviral regimens is
unlikely to work, and the cost of salvage therapy is relatively
high.17 Our study therefore suggests that it is not appro-
priate to use only the clinical and immunological criteria to
monitor the outcome of antiretroviral therapy. HIV RNA
measurement is more sensitive and could detect early
antiretroviral treatment failure in patients who may not
have clinical and immunological failures. A prospective
study to assess the cost-effectiveness of using HIV RNA as
a monitoring tool is necessary.
In conclusion, monitoring the outcome of antiretroviral
therapy using immunological and clinical criteria had a low
sensitivity to detect treatment failure. Our study, which was
limited by small numbers, was not able to demonstrate that
immunological or clinical criteria can adequately replace
virological criteria for treatment failure.
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